Skip to main content
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. — Investor Relations & Filings

Ticker · AARD ISIN · US0029421007 US Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US AARD

About Aardvark Therapeutics, Inc.

https://aardvarktherapeutics.com/

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel, small-molecule therapeutics. The company focuses on activating innate homeostatic pathways to address metabolic diseases and conditions associated with hunger. Its lead product candidate, ARD-101, is an oral investigational drug designed for the treatment of hyperphagia, particularly in rare genetic diseases. ARD-101 functions primarily within the digestive tract by activating bitter taste receptors (TAS2Rs), which triggers the local release of satiety hormones. These hormones then send signals to the brain to suppress hunger. The company aims to become a leader in treating hunger, with potential applications for obesity and related conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
Report Publication Announcement Classification · 82% confidence The document is a Form 8-K current report (3528 characters) under Item 2.02 “Results of Operations and Financial Condition,” stating that a press release with the Q1 2026 results is furnished as Exhibit 99.1. It does not include substantive financial data itself but merely announces the release and attachment of that press release. Per the “Menu vs. Meal” rule, short documents that state a report is furnished/attached are classified as Report Publication Announcements (RPA).
2026-05-07 English
8-K - AARDVARK THERAPEUTICS, INC. (0001774857) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions the company voluntarily pausing a Phase 3 clinical trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is an announcement of a significant event rather than a detailed financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-02-27 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content focuses on the departure of a Chief Operating Officer, appointment of a new COO, and related leadership changes. It includes details about a letter agreement and press releases about these management changes. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The primary subject is changes in senior management and board-level appointments. Therefore, this document fits the category of Board/Management Information (MANG). The document length (8266 characters) and detailed descriptions support this classification with high confidence.
2026-02-12 English
4 Filing
Director's Dealing
2026-02-11 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.